West Pharmaceutical Services (NYSE:WST) Posts Quarterly Earnings Results, Misses Estimates By $0.22 EPS

West Pharmaceutical Services (NYSE:WST) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.22), Briefing.com reports. West Pharmaceutical Services had a return on equity of 18.78% and a net margin of 18.25%. The business had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. During the same period in the prior year, the firm posted $2.11 EPS. West Pharmaceutical Services’s revenue for the quarter was down 6.9% on a year-over-year basis. West Pharmaceutical Services updated its FY 2024 guidance to 6.350-6.650 EPS.

West Pharmaceutical Services Price Performance

NYSE WST opened at $284.76 on Friday. West Pharmaceutical Services has a twelve month low of $265.00 and a twelve month high of $415.73. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.95 and a current ratio of 2.61. The stock has a market capitalization of $20.74 billion, a PE ratio of 37.57, a P/E/G ratio of 6.03 and a beta of 1.00. The stock has a 50-day simple moving average of $324.09 and a 200 day simple moving average of $355.79.

Insider Buying and Selling

In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The disclosure for this sale can be found here. 0.53% of the stock is owned by insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.